5-azacytidine treatment reorganizes genomic histone modification patterns

Methylation of DNA in combination with histone modifications establishes an epigenetic code that ensures the proper control of gene expression. Although DNA methyltransferases have been shown to interact with histone methyltransferases such as EZH2 (which methylates histone H3 on lysine 27) and G9a (which methylates histone H3 on lysine 9), the relationship between DNA methylation and repressive histone marks has not been fully studied. In cancer cells, promoters of genes are often aberrantly methylated. Accordingly, 5-azacytidine (a DNA demethylating drug) is used for treating patients with myelodysplastic syndrome. However, no genome-scale studies of the effects of this drug have been reported. In this work, we report the effects of 5-azacytidine on global gene expression and analyze ~24,000 human promoters using ChIP-chip to determine how 5-azacytidine treatment effects H3K27me3 and H3K9me3 levels. We found that (1) 5-azacytidine treatment results in large changes in gene regulation with distinct functional categories of genes showing increased (e.g. C2H2 zinc finger transcription factors) and decreased (e.g. genes involved in regulation of mitochondria and oxidoreductase activity) levels; (2) most genes that show altered expression are not regulated by promoters that display DNA methylation prior to the treatment; (3) certain gene classes switch their repression mark upon treatment with 5-azacytidine (from H3K27me3 to H3K9me3 and vice versa); and (4) most changes in gene expression are not due to relief of repression mediated by DNA or histone methylation. Updated supplementary link: http://www.landesbioscience.com/journals/epigenetics/article/11409/KomashkoEPI5-3-Sup.pdf

[1]  R. Tuma.  Epigenetic therapies move into new territory, but how exactly do they work? , 2009, Journal of the National Cancer Institute.

[2]  Chris A. Nasrallah,et al.  Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. , 2009, Blood.

[3]  J. Issa,et al.  Targeting DNA Methylation , 2009, Clinical Cancer Research.

[4]  H. Cedar,et al.  Linking DNA methylation and histone modification: patterns and paradigms , 2009, Nature Reviews Genetics.

[5]  R. Dahiya,et al.  BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. , 2009, Carcinogenesis.

[6]  S. Squazzo,et al.  Using ChIP-chip technology to reveal common principles of transcriptional repression in normal and cancer cells. , 2008, Genome research.

[7]  Qian Tao,et al.  DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. , 2008, Human molecular genetics.

[8]  Matteo Pellegrini,et al.  Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. , 2008, Cell stem cell.

[9]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[10]  J. Issa.  DNA methylation as a therapeutic target in cancer. , 2008, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Bieda,et al.  Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes , 2007, Proceedings of the National Academy of Sciences.

[12]  Roland Green,et al.  Genome-scale ChIP-chip analysis using 10,000 human cells. , 2007, BioTechniques.

[13]  Peter A. Jones,et al.  DNA methylation: The nuts and bolts of repression , 2007, Journal of cellular physiology.

[14]  Simon Tavaré,et al.  beadarray: R classes and methods for Illumina bead-based data , 2007, Bioinform..

[15]  S. Pradhan,et al.  Functional cooperation between HP1 and DNMT1 mediates gene silencing. , 2007, Genes & development.

[16]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[17]  Henriette O'Geen,et al.  Identification of Genes Directly Regulated by the Oncogene ZNF217 Using Chromatin Immunoprecipitation (ChIP)-Chip Assays* , 2007, Journal of Biological Chemistry.

[18]  Michael B. Stadler,et al.  Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome , 2007, Nature Genetics.

[19]  D. Louis,et al.  Downregulation of RUNX3 and TES by hypermethylation in glioblastoma , 2007, Oncogene.

[20]  L. Godley,et al.  The use of hypomethylating agents in the treatment of hematologic malignancies , 2007, Leukemia & lymphoma.

[21]  Luke O Dannenberg,et al.  Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation , 2006, BMC Genomics.

[22]  A. Riggs,et al.  The Histone Methyltransferase SETDB1 and the DNA Methyltransferase DNMT3A Interact Directly and Localize to Promoters Silenced in Cancer Cells* , 2006, Journal of Biological Chemistry.

[23]  O. Yokosuka,et al.  Sequential gene expression changes in cancer cell lines after treatment with the demethylation agent 5‐Aza‐2′‐deoxycytidine , 2006, Cancer.

[24]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[25]  P. Taghavi,et al.  Association of BMI1 with Polycomb Bodies Is Dynamic and Requires PRC2/EZH2 and the Maintenance DNA Methyltransferase DNMT1 , 2005, Molecular and Cellular Biology.

[26]  Jonathan R Pollack,et al.  The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. , 2005, Cancer research.

[27]  Adrian E. Raftery,et al.  Normal uniform mixture differential gene expression detection for cDNA microarrays , 2005, BMC Bioinformatics.

[28]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[29]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[30]  Beatrix Ueberheide,et al.  Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. , 2003, Molecular cell.

[31]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[32]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[33]  A. Wolffe,et al.  DNA methylation in health and disease , 2000, Nature Reviews Genetics.

[34]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[35]  R. Foster,et al.  Cell-type specific and differential regulation of the human metallothionein genes. Correlation with DNA methylation and chromatin structure. , 1990, The Journal of biological chemistry.